首页> 外国专利> Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor and homologous growth controlling factors

Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor and homologous growth controlling factors

机译:基于转化生长因子和同源生长控制因子受体突变的癌症诊断预后和治疗

摘要

This invention is based on the discovery that the type II TGF-. beta. receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
机译:本发明基于发现II型TGF-β。 Beta。受体(RII)是一种癌症抑制基因,在大约25%的结肠癌中被基因灭活(突变),包括几乎所有被确定为突变体/微卫星不稳定性/ RER的结肠癌。提供了用于检测RII失活以用于癌症诊断或预后的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号